Literature DB >> 23362095

Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.

Tomoko Hyodo1, Takamichi Murakami, Yasuharu Imai, Masahiro Okada, Masatoshi Hori, Yuki Kagawa, Sachiyo Kogita, Seishi Kumano, Masatoshi Kudo, Teruhito Mochizuki.   

Abstract

PURPOSE: To identify patient characteristics and magnetic resonance (MR) imaging findings associated with subsequent hypervascularization in hypovascular nodules that show hypointensity on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with chronic liver diseases.
MATERIALS AND METHODS: Institutional review board approval was obtained, and informed consent was waived. At multiple follow-up gadoxetic acid-enhanced MR imaging examinations of 68 patients, 160 hypovascular nodules were retrospectively reviewed. A Cox regression model for hypervascularization was developed to explore the association of baseline characteristics, including patient factors (Child-Pugh classification, etiology of liver disease, history of local therapy for hepatocellular carcinoma [HCC], and coexistence of hypervascular HCC) and MR imaging findings (fat content, signal intensity on T2-weighted images, and nodule size). In addition, the growth rate was calculated as the reciprocal of tumor volume doubling time to investigate its relationship with subsequent hypervascularization by using receiver operating characteristic and Kaplan-Meier analyses.
RESULTS: The prevalence of subsequent hypervascularization was 31% (50 of 160 nodules). Independent Cox multivariable predictors of increased risk of hypervascularization were hyperintensity on T2-weighted images (hazard ratio [HR] = 8.7; 95% confidence interval [CI]: 3.6, 20.8), previous local therapy for hypervascular HCC (HR = 5.0; 95% CI: 1.8, 13.6), Child-Pugh B cirrhosis (HR = 3.6; 95% CI: 1.4, 9.5) and coexistence of hypervascular HCC (HR = 2.0; 95% CI: 1.0, 3.8). The mean growth rate was significantly higher in nodules that showed subsequent hypervascularization than in those without hypervascularization. Kaplan-Meier analysis based on the receiver operating characteristic cutoff level (1.8 × 10(-3)/day [tumor volume doubling time, 542 days]) showed that nodules with a higher growth rate had a significantly higher incidence of hypervascularization (P = 5.2 × 10(-8), log-rank test).
CONCLUSION: Hyperintensity on T2-weighted images is an independent and strong risk factor at baseline for subsequent hypervascularization in hypovascular nodules in patients with chronic liver disease. Tumor volume doubling time of less than 542 days was associated with a high rate of subsequent hypervascularization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362095     DOI: 10.1148/radiol.12112677

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  43 in total

1.  Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study.

Authors:  Tatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2015-09-15       Impact factor: 7.527

2.  Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.

Authors:  Megumi Matsuda; Takaharu Tsuda; Shinji Yoshioka; Shigetoshi Murata; Hiroaki Tanaka; Masashi Hirooka; Yoichi Hiasa; Teruhito Mochizuki
Journal:  Jpn J Radiol       Date:  2014-05-24       Impact factor: 2.374

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

5.  Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis.

Authors:  Atsushi Higaki; Katsuyoshi Ito; Tsutomu Tamada; Teruki Sone; Akihiko Kanki; Yasufumi Noda; Kazuya Yasokawa; Akira Yamamoto
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

6.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

7.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

8.  Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.

Authors:  Dong Ho Lee; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

9.  IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.

Authors:  Min Yao; Li Wang; Junling Yang; Xiaodi Yan; Yin Cai; Dengfu Yao
Journal:  Tumour Biol       Date:  2016-09-13

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.